The corporate venturing units of three healthcare companies have joined a consortium investing in the $45m series A round of Effector Therapeutics, a US-based biopharmaceutical company named after the eponymous molecule that selectively binds to a protein and regulates its biological activity.
Novartis Venture Funds, GlaxoSmithKline’s SR One and Astellas Venture Management joined with venture capital (VC) firms, including US Venture Partners, Abingworth, Osage University Partners and Mission Bay Capital, in backing Effector.
Effector focuses on developing small molecule drugs to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?